Ticagrelor in Severe Community Acquired Pneumonia

Summary

The purpose of this study is to determine if the drug ticagrelor will be an effective treatment for patients with severe community acquired pneumonia. The primary objective is to reduce all-cause mortality in the ticagrelor group compared to the placebo group.

Timeline

Start

2014-08

Primary completion

2015-12

Completion

2015-12

Outcome

Missed primary endpoint

Stopped (Enrollment): “poor enrollment, unable to meet recruitment goals”

registry analysis (superiority or other test); Ticagrelor vs Placebo; p = 0.41; Chi-squared NCT01998399 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ticagrelor	Small molecule	90 mg	—

Indications